BIO:ON Insight #1 · Jun 7, 2026
Three "impossible" problems, one week. What did they have in common?
An AI-designed vaccine clears its first human trial, a KRAS drug doubles pancreatic cancer survival, and CRISPR Therapeutics pushes gene editing into heart disease. Three 'impossible' problems, one week.
What I learned this week
Looking at the three stories together, it feels like the breakthroughs came less from finding the right answer and more from asking a different question. Instead of "how do we grab KRAS?", someone asked "what if we grab the thing that moves it?" Instead of "how do we find a good antigen?", someone designed one from scratch. Next time a big result lands, ask "why here, and why now?" That one question is what separates reading a headline from reading the field. See you next issue. 🙏
Yaehyun Lee · Quoted from the Editor's Insight I wrote for this issue.
Stories in this issue
- Clinical Trials
Cambridge's AI-designed vaccine clears a human trial
- Clinical Trials
Daraxonrasib improves survival in a pancreatic cancer Phase 3
Revolution Medicinesdaraxonrasib
- Pipeline Analysis
CRISPR Therapeutics' gene-editing pipeline
CRISPR Therapeutics
AI summary
- 1Cambridge's vaccine, designed from scratch by AI, became the first of its kind to clear a Phase 1 human trial.
- 2Revolution Medicines' KRAS drug daraxonrasib doubled pancreatic cancer survival in Phase 3 (6.7 → 13.2 months).
- 3After Casgevy's approval, CRISPR Therapeutics is extending gene editing into cardiovascular disease and blood cancers.
Relevant rolesR&DClinical developmentBD
Summary and tags generated by AI from the issue text.
References
- 1.Cambridge AI-designed vaccine clears first human trial (opens in a new tab)
Crypto Briefing / University of Cambridge
- 2.daraxonrasib Phase 3 in pancreatic cancer — ScienceAlert (opens in a new tab)
Revolution Medicines
- 3.
Related insights
Other issues covering the same companies, drugs or topics